Henry Schein (HSIC) : Carderock Capital Management Inc reduced its stake in Henry Schein by 0.35% during the most recent quarter end. The investment management company now holds a total of 33,536 shares of Henry Schein which is valued at $5,701,120 after selling 119 shares in Henry Schein , the firm said in a disclosure report filed with the SEC on May 3, 2016.Henry Schein makes up approximately 2.97% of Carderock Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Cambridge Investment Research Advisors reduced its stake in HSIC by selling 16 shares or 0.85% in the most recent quarter. The Hedge Fund company now holds 1,856 shares of HSIC which is valued at $315,520. Henry Schein makes up approx 0.01% of Cambridge Investment Research Advisors’s portfolio.Duncker Streett Co Inc reduced its stake in HSIC by selling 2,426 shares or 10.31% in the most recent quarter. The Hedge Fund company now holds 21,097 shares of HSIC which is valued at $3,559,064. Henry Schein makes up approx 1.31% of Duncker Streett Co Inc’s portfolio.North Point Portfolio Managers Corpoh boosted its stake in HSIC in the latest quarter, The investment management firm added 718 additional shares and now holds a total of 114,990 shares of Henry Schein which is valued at $19,398,813. Henry Schein makes up approx 3.73% of North Point Portfolio Managers Corpoh’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in HSIC in the latest quarter, The investment management firm added 21,155 additional shares and now holds a total of 36,490 shares of Henry Schein which is valued at $6,233,587. Henry Schein makes up approx 0.03% of Bnp Paribas Arbitrage Sa’s portfolio.
Henry Schein opened for trading at $171.12 and hit $172.31 on the upside on Tuesday, eventually ending the session at $172.23, with a gain of 0.88% or 1.5 points. The heightened volatility saw the trading volume jump to 2,95,949 shares. Company has a market cap of $14,134 M.
On the company’s financial health, Henry Schein reported $1.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 3, 2016. Analyst had a consensus of $1.39. The company had revenue of $2712.96 million for the quarter, compared to analysts expectations of $2667.28 million. The company’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.28 EPS.
Many Wall Street Analysts have commented on Henry Schein. Company shares were Reiterated by Barrington Research on May 4, 2016 to “Outperform”, Firm has raised the Price Target to $ 188 from a previous price target of $182 .Henry Schein was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016. Barrington Research Upgraded Henry Schein on Mar 1, 2016 to ” Outperform”, Price Target of the shares are set at $182.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.